Results 131 to 140 of about 180,829 (383)

B cells reappear less mature and more activated after their anti-CD20–mediated depletion in multiple sclerosis

open access: yesProceedings of the National Academy of Sciences of the United States of America, 2020
Significance Anti-CD20–mediated B cell depletion is a highly effective therapy in MS. However, long-term effects of this approach on the immune system are not yet characterized in detail.
Nitzan Nissimov   +6 more
semanticscholar   +1 more source

Periodontitis Induces B Cell‐Macrophage Crosstalk to Exacerbate Glucose Dysregulation in Obesity

open access: yesAdvanced Science, EarlyView.
In obesity, periodontitis exacerbates hyperglycemia and exhibits a liver‐centric preference for glucose regulation. This occurs through a periodontitis‐driven circuit between pathogenic B cells and hepatic macrophages. Their reciprocal expansion, orchestrated by the NLRP3/IL‐18 signaling pathway, amplifies metabolic inflammation and disrupts glucose ...
Wen‐Zhen Lin   +19 more
wiley   +1 more source

Cationic mRNA Lipid Nanoparticles for Ex Vivo NanoCAR‐T Cell Engineering

open access: yesAdvanced Science, EarlyView.
This study compares charge‑neutral and cationic lipidnanoparticles (LNPs) for ex vivo mRNA delivery to T cells, revealing distinctdependencies on medium composition and T cell activation. Where conventional LNPs benefit from ApoE‐dependent T cell targeting, cationic DOTAP‑modified LNPs mediate unspecific charge‑dependent transfection.
Laure Harinck   +9 more
wiley   +1 more source

PRELID1 and VDAC3 Coordinate a Senescence‐Like State in Germinal Center B Cells to Promote IL‐7–Driven Antitumor Immunity in Colorectal Cancer

open access: yesAdvanced Science, EarlyView.
Colorectal cancer is characterized by an immunosuppressive microenvironment that limits immunotherapy efficacy. We identify a senescence‐like state in germinal center B cells driven by the PRELID1–VDAC3 axis, which promotes IL‐7 secretion, alleviates CD8+ T‐cell exhaustion, and enhances antitumor immunity. Targeting this pathway improves responsiveness
Yuhan Liao   +8 more
wiley   +1 more source

Tumor‐Induced Splenic Remodeling: Mechanisms of Systemic Immunosuppression and Emerging Therapeutic Opportunities

open access: yesAdvanced Science, EarlyView.
ABSTRACT Despite the transformative impact of cancer immunotherapies such as immune checkpoint blockade, durable clinical responses remain limited. Increasing evidence indicates that antitumor immunity is governed not only by the tumor microenvironment, but also by systemic immune regulation mediated by peripheral immune organs. Among these, the spleen
Yuehua Liu, Xiaoqian Nie, Xiaofei Gao
wiley   +1 more source

Mature Tertiary Lymphoid Structures Indicate Good Chemotherapy Response and Prognosis in Advanced Colorectal Cancer

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
In advanced colorectal cancer, tumors with mature tertiary lymphoid structures (TLS) exhibited abundant infiltration of CD3‐ and CD8‐positive lymphocytes in both primary and metastatic sites, indicating an activated immune response. The presence of mature TLS was also associated with favorable chemotherapy sensitivity and improved prognosis.
Nobuhiro Hosoi   +9 more
wiley   +1 more source

CAQ Corner: Immune‐mediated complications

open access: yes, 2022
Liver Transplantation, EarlyView.
Mary Thomson, John R. Lake
wiley   +1 more source

The origin of human CD20+ T cells: a stolen identity?

open access: yesFrontiers in Immunology
Human T cells expressing CD20 play an important role in the defense against virus and cancer and are central in the pathogenesis of both malignancies and various autoimmune disorders.
Marina Rode von Essen   +3 more
doaj   +1 more source

Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. [PDF]

open access: yes, 2017
BackgroundThe CXCR4-CXCL12 axis plays an important role in the chronic lymphocytic leukemia (CLL)-microenvironment interaction. Overexpression of CXCR4 has been reported in different hematological malignancies including CLL.
Amaya-Chanaga, Carlos I   +18 more
core   +4 more sources

Fixed‐Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Mosunetuzumab is approved as an intravenous (IV) formulation for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies. A subcutaneous (SC) formulation, aiming to improve patient safety and convenience, has been developed.
Nancy L. Bartlett   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy